Oliveira A L, de Souza M, Carvalho-Dias V M H, Ruiz M A, Silla L, Tanaka P Yurie, Simões B P, Trabasso P, Seber A, Lotfi C J, Zanichelli M A, Araujo V R, Godoy C, Maiolino A, Urakawa P, Cunha C A, de Souza C A, Pasquini R, Nucci M
Hospital Universitário, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Bone Marrow Transplant. 2007 Jun;39(12):775-81. doi: 10.1038/sj.bmt.1705677. Epub 2007 Apr 16.
The incidence of Gram-negative bacteremia has increased in hematopoietic stem cell transplant (HSCT) recipients. We prospectively collected data from 13 Brazilian HSCT centers to characterize the epidemiology of bacteremia occurring early post transplant, and to identify factors associated with infection due to multi-drug-resistant (MDR) Gram-negative isolates. MDR was defined as an isolate with resistance to at least two of the following: third- or fourth-generation cephalosporins, carbapenems or piperacillin-tazobactam. Among 411 HSCT, fever occurred in 333, and 91 developed bacteremia (118 isolates): 47% owing to Gram-positive, 37% owing to Gram-negative, and 16% caused by Gram-positive and Gram-negative bacteria. Pseudomonas aeruginosa (22%), Klebsiella pneumoniae (19%) and Escherichia coli (17%) accounted for the majority of Gram-negative isolates, and 37% were MDR. These isolates were recovered from 20 patients, representing 5% of all 411 HSCT and 22% of the episodes with bacteremia. By multivariate analysis, treatment with third-generation cephalosporins (odds ratio (OR) 10.65, 95% confidence interval (CI) 3.75-30.27) and being at one of the hospitals (OR 9.47, 95% CI 2.60-34.40) were associated with infection due to MDR Gram-negative isolates. These findings may have important clinical implications in the decision of giving prophylaxis and selecting the empiric antibiotic regimen.
造血干细胞移植(HSCT)受者中革兰氏阴性菌血症的发生率有所上升。我们前瞻性地收集了来自巴西13个HSCT中心的数据,以描述移植后早期发生的菌血症的流行病学特征,并确定与多重耐药(MDR)革兰氏阴性菌感染相关的因素。MDR被定义为对以下至少两种药物耐药的菌株:第三代或第四代头孢菌素、碳青霉烯类或哌拉西林-他唑巴坦。在411例HSCT中,333例出现发热,91例发生菌血症(118株分离菌):47%由革兰氏阳性菌引起,37%由革兰氏阴性菌引起,16%由革兰氏阳性菌和革兰氏阴性菌共同引起。铜绿假单胞菌(22%)、肺炎克雷伯菌(19%)和大肠埃希菌(17%)占革兰氏阴性菌分离株的大多数,37%为MDR。这些分离株从20例患者中分离得到,占所有411例HSCT的5%,占菌血症发作的22%。多因素分析显示,使用第三代头孢菌素治疗(比值比(OR)10.65,95%置信区间(CI)3.75 - 30.27)以及在其中一家医院治疗(OR 9.47,95% CI 2.60 - 34.40)与MDR革兰氏阴性菌感染相关。这些发现可能对预防决策和选择经验性抗生素治疗方案具有重要的临床意义。